Span Divergent Limited - Intimation of Receipt of In-principle approval from BSE Limited for Preferential Issue of Equity Shares
FUNDRAISE
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 20 Mar 2026, 12:57 PM IST · BSE ID: f9d6a97a-1d4e-40d0-9881-384125e0d684
View Original BSE Filing (PDF)
💡
In Simple Terms
Span Diagnostics renamed Span Divergent just got bank approval to sell 18 lakh new shares to a non-promoter investor at Rs. 32.16 per share.
🤖 AI Summary
- Span Divergent receives BSE in-principle approval for 18,01,481 equity shares preferential issue
- Issue price Rs. 32.16 per share (face value Rs. 10, premium Rs. 22.16)
- Allottee is Mr. Neev Nirav Jogani, classified as non-promoter
- BSE approval Reference LOD/PREF/GB/FIP/1914/2025-26 dated March 19, 2026
- Company must obtain undertaking from allottee on no intra-day trading until allotment
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity shares to be issued
18,01,481 shares
Face value per share
Rs. 10
Issue price per share
Rs. 32.16
Premium per share
Rs. 22.16
Gross proceeds (at issue price)
Rs. 57,975,785.96
BSE approval reference
LOD/PREF/GB/FIP/1914/2025-26
🏢 How This Affects the Company
Issue is to a non-promoter, indicating external capital infusion. Exact use of proceeds not disclosed in this filing. Impact on business operations or strategic direction cannot be determined without disclosure of deployment plans.
Preferential issue will add 18,01,481 equity shares to capital structure. At Rs. 32.16 per share, gross proceeds will be Rs. 57,975,785.96 before any underwriting or allotment costs. Impact on share capital and premium reserve depends on final allotment timing and date.
BSE has flagged requirement for internal controls to monitor allottee trading activity post-allotment to prevent ICDR Regulation violations. Non-compliance with 20-day listing application deadline post-allotment invites SEBI fines under circular SEBI/HO/CFD/PoD-2/P/CIR/2023/00094.
👥 What This Means For Shareholders
✅
Action Required
Monitor company disclosures for allotment announcement and listing application filing within 20 days thereof; no shareholder action required at this approval stage.
👤
Who Is Affected
All existing shareholders will see ownership dilution upon allotment of 18,01,481 new shares. Effect on EPS and voting power depends on allotment date and final capital base.
🔍
Management Signal
Preferential issue to non-promoter suggests management is accessing external capital; lack of proceeds disclosure indicates either confidentiality or strategic incompleteness in this interim disclosure.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Allotment announcement and credit of shares to allottee demat account within 30-45 days.
Listing application filing with BSE within 20 days of allotment date per SEBI regulation.
Disclosure of proceeds deployment use in next Board meeting or quarterly regulatory filing.
MEDIUM RISK
Regulatory compliance deadline of 20 days post-allotment for listing application is tight. Non-compliance triggers SEBI fines. Internal control gaps on allottee trading can delay listing approval.
💡 Investor Takeaway
Span Divergent cleared BSE regulatory gate for 18,01,481 preferential share issuance at Rs. 32.16 per share, generating gross proceeds of approximately Rs. 57.98 million. Allotment and listing must follow within statutory timelines or incur SEBI penalties. Deployment of capital not yet disclosed.
⚖️ Strengths & Concerns
✅ Positives
- In-principle approval from BSE obtained, removing primary regulatory hurdle for issue execution.
- Non-promoter status of allottee signals external institutional or investor participation and confidence.
⚠️ Concerns
- Proceeds deployment not disclosed; no information on use of capital or strategic rationale.
- Company must complete allotment and file listing application within 20 days or face SEBI penalties.
📅 Company Track Record
Company name changed from Span Diagnostics Limited to Span Divergent Limited. No previous BSE filings available. Limited public track record accessible for this renamed entity.
Based on publicly available historical data. For context only.